Thomas Beck leads the New York intellectual property litigation group, and focuses on complex chemical and pharmaceutical patent litigation matters. Notable results include a two-week jury trial win for Sunovion in Hatch-Waxman litigation against Mylan concerning the asthma drug Xopenex (levalbuterol), winning lost profits, plus a reasonable royalty and a jury finding of willful infringement. He has counselled clients regarding drug analogues, fusion proteins, recombinant DNA techniques and analytical methods and medical device technologies.
Tom also regularly presents on Hatch-Waxman issues at the ACI Paragraph IV litigation conferences in New York (having appeared at the 2014, 2011, 2008 and 2007 conferences) and also spoke at the Momentum Paragraph IV conference in New York in 2013.
WWL says: Thomas Beck focuses his practice on complex chemical and pharmaceutical patent litigation matters, and is described by clients as “formidably intelligent and skilful”
This biography is an extract from Who's Who Legal: Patents which can be purchased from our Shop.